Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of intravitreal micro-insert (0.18mg of fluocinolone acetonide using the Durasert technology) for the treatment of chronic uveitis affecting the posterior segment of the eye

Next Previous
Search
Trial Profile

A study of intravitreal micro-insert (0.18mg of fluocinolone acetonide using the Durasert technology) for the treatment of chronic uveitis affecting the posterior segment of the eye

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Posterior uveitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Ocumension Therapeutics

    • Most Recent Events

    • 15 Nov 2019 New trial record
    • 07 Nov 2019 According to an EyePoint Pharmaceuticals media release, Ocumension Therapeutics has received IND approval in China. This trial will support regulatory approval for the treatment of chronic uveitis affecting the posterior segment of the eye in China.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top